MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ('Annovis' or the 'Company'), a late-stage clinical ...
Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or ...
Presentation Operator Good, everyone, and welcome to the Energy's 4th-Quarter 2024 Financial Results Conference Call. All ...
Presentation Operator Ladies and gentlemen our program will begin momentarily please note that all lines will be placed ...